Sort
82,697 grants matching “vaccine development”
SUPPORT CONTRACT FOR THE NTP INTERAGENCY CENTER/VALIDATION OF ALT METHODS
$3,551,697David Allen · Integrated Laboratory Systems, Llc · N01 · FY2011 · ES
Influenza Vaccine Research and Development
$3,550,000Masaru Kanekiyo · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine
$3,549,203Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2011 · AI
A Genomics Based Investigation of the Determinants of Polymicrobial Infectious Disease Outcomes
$3,548,646David A Rasko · University Of Maryland Baltimore · U19 · FY2021 · AI
Vaccine Induced Immunity in the Young and Aged
$3,546,541Rafi Ahmed · Emory University · U19 · FY2017 · AI
Novel VLP-Based Mucosal and Sytemic HIV Vaccines
$3,545,652Jiri F Mestecky · University Of Alabama At Birmingham · U19 · FY2007 · AI
SUPPORT SERVICES OF THE HIV AIDS CLINICAL TRIAL NETWORKS
$3,544,291Barbara Driver · Westat, Inc. · N01 · FY2023 · HD
Operations and Management support component
$3,544,156Barton F Haynes · Duke University · UM1 · FY2016 · AI
CoVPN 3005: Efficacy, Immunogenicity, and Safety of Two SARS-CoV-2 Recombinant Protein Vaccines with Adjuvant in Adults 18 Years of Age and Older - LC 3
$3,544,100Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Development of rationally designed HIV vaccines
$3,542,953Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Development of a recombinant trimeric RSV-F vaccine (DS-Cav1)
$3,542,377Frank Arnold · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI
Boston HIV CTU
$3,541,665Daniel R Kuritzkes · Brigham And Women'S Hospital · UM1 · FY2024 · AI
Harvard University Center for AIDS Research
$3,540,479Bruce D Walker · Harvard University · P30 · FY2017 · AI
PHRU-Setshaba Clinical Trials Unit
$3,532,996Glenda E Gray · Wits Health Consortium (Pty), Ltd · UM1 · FY2021 · AI
Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases
$3,532,876Nikolai Petrovsky · Vaxine Pty Ltd · N01 · FY2020 · AI
Growth Control in Multiple Myeloma
$3,532,781Bart Barlogie · Univ Of Arkansas For Med Scis · P01 · FY2008 · CA
Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae
$3,532,691Jeanne M Marrazzo · University Of Alabama At Birmingham · N01 · FY2019 · AI
HIV Subtype C Alphavirus Vaccine Design &Development
$3,529,060Alphavax Human Vaccines, Inc. · U01 · FY2003 · AI
Development of an Adjuvant with Vaccines for Anthrax, and West Nile Virus (WNV)
$3,529,059Casey Koontz · · N01 · FY2014 · AI
South African Medical Research Council Clinical Trials Unit (MRC CTU)
$3,525,766Ameena Goga · Medical Research Council Of South Africa · UM1 · FY2019 · AI
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages
$3,522,123Barton F Haynes · Duke University · U19 · FY2021 · AI
Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse
$3,521,342Chang-Guo Zhan · University Of Kentucky · U01 · FY2021 · DA
Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse
$3,521,165Chang-Guo Zhan · University Of Kentucky · U01 · FY2020 · DA
Combined Approach to Broadly Protective AIDS Vaccines
$3,520,936University Of Washington · P01 · FY2004 · AI
PlanB2CureHIV (the 'PlanB' consortium)
$3,519,835James Even Voss · Scripps Research Institute, The · P01 · FY2025 · HL